Research — Comparison Tool

Peptide Comparison Tool

Pick up to three peptides and compare them side by side — evidence tier, protocol, safety profile, and the Atlas verdict. All data comes straight from the Atlas peptide database. Educational use only.

Peptide A

Peptide B

Peptide C

Attribute	BPC-157 Body Protection Compound-157, a synthetic 15-amino-acid gastric peptide analogue	TB-500 Synthetic thymosin-beta-4-derived research peptide, commonly associated with the Ac-LKKTETQ active region
Category	Healing	Healing
Evidence Tier	Preclinical Evidence	Preclinical Evidence
Overview	Synthetic peptide studied primarily for tissue repair, cytoprotection, and gastrointestinal healing pathways.	Thymosin beta-4 fragment research focused on tissue repair, wound healing, cell migration, and angiogenesis.
Mechanism	Proposed mechanisms include modulation of nitric-oxide signaling, VEGF and other growth-factor pathways, angiogenesis, fibroblast activity, and cytoprotective signaling. Most mechanistic work is from cell and animal models.	Thymosin-beta-4-related sequences bind actin and influence cytoskeletal dynamics, cell migration, angiogenesis, and wound repair. Specific 'TB-500' pharmacology is less standardized than the broader thymosin-beta-4 literature.
Common Dose	Community reference: 200–600 mcg/day with gradual titration. community sources' 2026 dosage guide describes roughly 250–500 mcg/day as the most common community range, with higher short-term ranges discussed for acute injury. There is no clinically validated human dose.	community sources experimental reference: 500–1,000 mcg/day. There is no validated human dose for 'TB-500' as a standardized drug.
Frequency	Once daily in the community protocol.	Once daily in the community current page.
Route	Subcutaneous in the community reference; human efficacy for any route remains unestablished.	Subcutaneous research use.
Timing	No evidence-based time-of-day requirement.	No established timing requirement.
Cycle Length	4–8 weeks	8–12 weeks
Formulation	10 mg vial	10 mg vial
Human Evidence	Meaningful controlled human efficacy evidence is absent. A few small or observational human reports have appeared, but they do not establish efficacy for tendon, ligament, muscle, gut, or systemic healing claims.	There is no established controlled human evidence for 'TB-500' as a standardized injury-recovery drug. Human studies of full thymosin beta-4 or related products should not be treated as direct proof for underground TB-500 formulations.
Preclinical Evidence	A large preclinical literature in rodents reports effects on tendon, ligament, muscle, bone, nerve, gastrointestinal injury, angiogenesis, and nitric-oxide signaling. The consistency of animal findings is the main reason the compound attracts interest, but the absence of comparable human trials is a major limitation.	Thymosin-beta-4 and related sequence research shows actin binding, cell migration, angiogenesis, and wound-repair effects in animals. Specific underground TB-500 products are not necessarily equivalent to the studied molecules.
Knowledge Gaps	The central gap is the absence of robust controlled human trials despite extensive animal literature. Human pharmacokinetics, bioavailability by route, dose-response, carcinogenesis/angiogenesis implications, long-term safety, and product identity/purity all remain unresolved.	Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.
Side Effects	Controlled human safety data are limited. Possible issues include injection-site reactions, headache, nausea, dizziness, fatigue and hypersensitivity. Because several proposed mechanisms involve angiogenesis or tissue-growth signaling, long-term systemic effects are uncertain.	Controlled human safety data are limited. Possible issues include injection-site reactions, headache, nausea, dizziness, fatigue and hypersensitivity. Because several proposed mechanisms involve angiogenesis or tissue-growth signaling, long-term systemic effects are uncertain.
Contraindications	No validated human contraindication profile exists. Pregnancy/breastfeeding, active malignancy, unexplained masses, major bleeding disorders or serious systemic illness warrant avoidance outside formal research/medical oversight.	No validated human contraindication profile exists. Pregnancy/breastfeeding, active malignancy, unexplained masses, major bleeding disorders or serious systemic illness warrant avoidance outside formal research/medical oversight.
Interactions	Formal interaction studies are lacking. Use with anticoagulants/antiplatelet drugs, growth-factor therapies, immunomodulators or other experimental repair peptides creates unknown additive risks.	Formal interaction studies are lacking. Use with anticoagulants/antiplatelet drugs, growth-factor therapies, immunomodulators or other experimental repair peptides creates unknown additive risks.
Monitoring	There is no validated biomarker-monitoring protocol. Track injury symptoms/function, adverse effects, CBC/CMP when clinically appropriate, and avoid using symptom improvement to delay diagnosis of structural injury.	No validated monitoring. Track objective tissue/injury function and adverse effects; CBC/CMP are general safety context. Athletes should note anti-doping restrictions around thymosin-beta-4-related substances.
Common Stacks	BPC-157 + TB-500 — Common recovery pairing that combines BPC-157's preclinical cytoprotective/angiogenic rationale with thymosin-beta-4-related cell-migration and repair biology. BPC-157 + GHK-Cu — Discussed for tissue/skin repair because the compounds act through different repair and matrix-remodeling pathways.	BPC-157 + TB-500 — Common recovery pairing intended to combine complementary repair pathways.
Atlas Verdict	BPC-157 may be one of the most compelling examples of the gap between peptide popularity and evidence quality. The animal healing data are extensive, but meaningful controlled human evidence is still missing. Atlas rates it preclinical: high scientific interest, low certainty for real-world human outcomes.	TB-500 is scientifically interesting for wound healing, angiogenesis, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

Gold-highlighted cells mark the stronger evidence tier in that row. Comparison data is drawn from the Atlas peptide database and reflects community reference ranges and published research — it is educational content, not medical advice. Always review the full protocol page before drawing conclusions.